Nearly half of veterans aged 60 to 89 reported a hypothetical willingness to undergo 10-year (vs. 5-year) surveillance if their physician recommended it.
Patients with one or two tubular adenomas <10 mm in size with low-grade dysplasia are said to have low-risk adenomas, and in the current surveillance guideline, they are recommended to undergo follow-up at 5 to 10 years. Most U.S. endoscopists advise these patients to undergo colonoscopy at 5 years, although the yield of surveillance is low.
In a survey of some 350 Veterans Administration hospital patients with low-risk adenomas (aged 60–89 years; 98% male), participants were presented with a hypothetical scenario in which a provider informs a patient due for a surveillance exam about the low risk for colorectal cancer. They then answered questions about their attitudes toward a 5-year versus 10-year interval for surveillance. Results were as follows:
The majority (89%) were interested in a 5-year surveillance interval, but 45% were comfortable waiting 10 years if recommended by their physician.
Trust in physicians was associated with a higher comfort level for waiting 10 years, and perceived effectiveness of colonoscopy and greater worry about colorectal cancer were associated with a lower comfort level.
Half of respondents were comfortable stopping surveillance for poor health.
Factors associated with less comfort with stopping included worrying about colorectal cancer (odds ratio, 0.7), perceived effectiveness of colonoscopy (OR, 0.8), and black race (OR, 0.4).
Reviewing Author
DisclosuresConsultant/Advisory BoardOlympus Corporation America; Boston Scientific
Speaker’s BureauOlympus
Grant/Research SupportMedtronic; Boston Scientific; Colonary Solutions; Paion Medical; Medivators; Braintree Laboratories
Editorial BoardsWorld Journal of Gastroenterology; The Journal of Clinical Gastroenterology; Techniques in Gastrointestinal Endoscopy; Gastroenterology & Hepatology; Expert Review of Gastroenterology & Hepatology; Medscape Gastroenterology; World Journal of Gastrointestinal Pharmacology and Therapeutics; Annals of Gastroenterology & Hepatology; World Journal of Gastrointestinal Oncology; Comparative Effectiveness Research; Journal of Anesthesia & Clinical Research; Gastroenterology; World Journal of Gastrointestinal Pathophysiology; Gastroenterology Research and Practice; GI & Hepatology News; Gastroenterology Report; Clinical Epidemiology Reviews; JSM Gastroenterology and Hepatology; GI Journal Watch; Austin Journal of Gastroenterology; World Journal of Gastrointestinal Pharmacology & Therapeutics
Leadership Positions in Professional SocietiesAmerican Society for Gastrointestinal Endoscopy (Treasurer); US Multi-Society Task Force (AGA, ACG, ASGE) (Chair)
DisclosuresConsultant/Advisory BoardOlympus Corporation America; Boston Scientific
Speaker’s BureauOlympus
Grant/Research SupportMedtronic; Boston Scientific; Colonary Solutions; Paion Medical; Medivators; Braintree Laboratories
Editorial BoardsWorld Journal of Gastroenterology; The Journal of Clinical Gastroenterology; Techniques in Gastrointestinal Endoscopy; Gastroenterology & Hepatology; Expert Review of Gastroenterology & Hepatology; Medscape Gastroenterology; World Journal of Gastrointestinal Pharmacology and Therapeutics; Annals of Gastroenterology & Hepatology; World Journal of Gastrointestinal Oncology; Comparative Effectiveness Research; Journal of Anesthesia & Clinical Research; Gastroenterology; World Journal of Gastrointestinal Pathophysiology; Gastroenterology Research and Practice; GI & Hepatology News; Gastroenterology Report; Clinical Epidemiology Reviews; JSM Gastroenterology and Hepatology; GI Journal Watch; Austin Journal of Gastroenterology; World Journal of Gastrointestinal Pharmacology & Therapeutics
Leadership Positions in Professional SocietiesAmerican Society for Gastrointestinal Endoscopy (Treasurer); US Multi-Society Task Force (AGA, ACG, ASGE) (Chair)
Citation(s):
Maratt JK et al. Veterans' attitudes towards de-intensification of surveillance colonoscopy for low-risk adenomas. Clin Gastroenterol Hepatol 2018 Mar 30; [e-pub]. (https://doi.org/10.1016/j.cgh.2018.03.029)
Comment
Recent studies suggest that the single most important factor in predicting advanced adenomas at surveillance colonoscopy is the adenoma detection rate of the physician who performed the baseline procedure. It is fair for patients to be offered 10-year intervals, but what patients should really be interested in is their physician's adenoma detection rate. Expanding the interval to 10 years for patients of physicians with high ADRs and low-risk adenomas is quite reasonable, but the practice of expanding intervals for patients of doctors with low baseline ADRs and adenomas could be dangerous.